Ultimately the issue is the licensing of the patent (which is likely retained by Emory or its non-profit affiliate), and under Bayh-Dole universities can exclusively license it.
By introducing non-exclusive licensing, then you have a competitive situation in which the lower-cost manufacturer can provide the drug more cheaply but at the same quality and monopolistic pricing schedules cannot be introduced by the likes of Merck.
The taxpayer benefit is lower cost of drugs invented with taxpayer funds.
By introducing non-exclusive licensing, then you have a competitive situation in which the lower-cost manufacturer can provide the drug more cheaply but at the same quality and monopolistic pricing schedules cannot be introduced by the likes of Merck.
The taxpayer benefit is lower cost of drugs invented with taxpayer funds.